This firm fixed-price purchase order contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Illumina, Inc., a for-profit manufacturer of sequencing and array-based genomic analysis solutions. The $98,094.00 contract is for the provision of laboratory equipment, with no set-aside designation. Based on Illumina's past federal contract work, the equipment is likely to include Next-Generation DNA sequencing systems, reagents, and related...
This is a firm fixed price purchase order contract awarded to Illumina, Inc., a manufacturer of genomic sequencing and analysis products, by the Centers for Disease Control and Prevention (CDC). The $90,260.40 contract does not have a set-aside designation. Illumina has previously provided sequencing instruments, reagents, and related services to support genomic research and diagnostics across various federal agencies. This award appears to be for the provision of Illumina's sequencing...
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract, valued at $223,532.40, is for the maintenance and services of Illumina sequencing instruments. The contract has an ultimate completion date of April 4, 2025 and does not utilize any set-aside designations. Illumina, headquartered in San Diego, California, is a...
This is a $249,575 firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the procurement of laboratory systems and does not have a set-aside designation. Illumina has been awarded multiple prime federal contracts and grants across agencies like the NIH, USDA, VA, and FDA, primarily for the provision of advanced sequencing...
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $236,726.60 contract is for a service agreement to provide the CDC with Illumina's advanced sequencing instruments, reagents, consumables, and bioinformatics software. The contract does not have a set-aside designation and has an ultimate completion date of August 31, 2026....
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing and analysis instruments and reagents, for the maintenance of laboratory equipment. The contract has a ceiling value of $14,329.00 and a performance period ending on July 20, 2024. The award does not utilize any set-aside provisions. Illumina has a history of providing sequencing systems, reagents, and services to support...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing and analysis instruments and reagents. The $83,968.67 contract is for the provision of unspecified goods and services, with no set-aside designation. Illumina has a history of providing sequencing systems, consumables, and related services to federal agencies like the NIH, USDA, and VA for genomic research and diagnostic applications....
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing systems and related products. The contract is for the maintenance, repair, and support of Illumina's NovaSeq 6000 and MiSeq sequencing instruments over a 2-year period, with a ceiling value of $139,336.76. This contract does not have a set-aside designation. Illumina has previously received prime federal contracts and...
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for a maintenance agreement with a total ceiling value of $75,716.00 and a period of performance through June 10, 2021. The contract does not have a set-aside designation. Illumina has previously received prime federal contracts and subcontracts from agencies such as the...
This is a firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Illumina, Inc., a manufacturer of genetic and genomic analysis equipment and reagents. The $95,931.00 contract is for the delivery of laboratory equipment with no set-aside designation. Illumina has a history of providing sequencing instruments, reagents, and related services to support genomic research and diagnostics across federal agencies such as the...